±¹¼ÒÀûÀ¸·Î ÁøÇàµÈ ºñ¼Ò¼¼Æ÷Æó¾ÏÀÇ ¹æ»ç¼±Ä¡·á ¼ºÀû
The Results of Radiation Therapy in Locally Advanced Non-Small Cell Lung Cancer

´ëÇÑÄ¡·á¹æ»ç¼±°úÇÐȸÁö 1997³â 15±Ç 3È£ p.233 ~ p.242

±è¹Ì¼÷(Kim Mi-Sook) - ¿øÀڷº´¿ø ¹æ»ç¼±Á¾¾çÇаú
°­À±±¸(Kang Yoon-Koo) - ¿øÀڷº´¿ø ³»°ú
ÀÌÃáÅÃ(Lee Choon-Taek) - ¿øÀڷº´¿ø ³»°ú
·ù¼º·Ä(Yoo Seoung-Yul) - ¿øÀڷº´¿ø ¹æ»ç¼±Á¾¾çÇаú
Á¶Ã¶±¸(Cho Chul-Koo) - ¿øÀڷº´¿ø ¹æ»ç¼±Á¾¾çÇаú
À¯ÇüÁØ(Yoo Hyung-Jun) - ¿øÀڷº´¿ø ¹æ»ç¼±Á¾¾çÇаú
±èÀ翵(Kim Jae-Young) - ¿øÀڷº´¿ø ¹æ»ç¼±Á¾¾çÇаú
±èÅÂÀ¯(Kim Tae-You) - ¿øÀڷº´¿ø ³»°ú

Abstract

¸ñ Àû: ºñ¼Ò¼¼Æ÷Æó¾ÏÀ¸·Î ±ÙÄ¡Àû ¹æ»ç¼±Ä¡·á¸¦ ½ÃÇà¹ÞÀº ȯÀÚÀÇ »ýÁ¸À² ¹× ¿¹ÈÄÀÎÀÚ¸¦ ¾Ë¾Æº¸±â À§ÇÏ¿© º» ¿¬±¸¸¦ ½ÃÇàÇÏ¿´´Ù.

¹æ ¹ý: 1992³â 1¿ùºÎÅÍ 1993³â 12¿ù±îÁö ¼ö¼úÀÌ ºÒ°¡´ÉÇÑ ºñ¼Ò¼¼Æ÷Æó¾ÏÀ¸·Î ¿øÀڷº´¿ø Ä¡·á¹æ»ç¼±°ú¿¡¼­ 40Gy ÀÌ»óÀÇ ±ÙÄ¡Àû ¹æ»ç¼±Ä¡·á¸¦ ½ÃÇà¹ÞÀº 62¸íÀÇ È¯ÀÚ¿¡ ´ëÇØ ÈÄÇâÀûÀ¸·Î Ä¡·á °á°ú¸¦ ºÐ¼®ÇÏ¿´´Ù. º´±âº° ºÐÆ÷´Â º´±â IIIA 14¿¹, º´±â IIIB 48¿¹¿´´Ù. ¹æ»ç¼±Ä¡·á´Â ÀÏÀÏ ¼±·® 1.8-2.0Gy¾¿ ÁÖ 5ȸ·Î ¿ø¹ßº´¼Ò¿¡ ÃÑ 40.0-70.2GyÀÇ ¹æ»ç¼±À» Á¶»çÇÏ¿´´Ù. ȯÀÚÁß 37¿¹¿¡¼­ À¯µµ È­Çпä¹ýÀ» ½ÃÇàÇÏ¿´´Ù.

°á °ú: ¹æ»ç¼± Ä¡·á ÈÄ ¹ÝÀÀÀº ¿ÏÀü °üÇØ°¡ 3¿¹, ºÎºÐ°üÇØ°¡ 34¿¹¿´´Ù. ±×¿Ü´Â ¹«¹ÝÀÀÀÌ¿´´Ù. ÀüüȯÀÚÀÇ Áß¾Ó »ýÁ¸±â°£Àº 11°³¿ùÀ̾úÀ¸¸ç 1³â »ýÁ¸À²Àº 45.0%, 2³â »ýÁ¸À²Àº 14.3%¿´°í 5³â »ýÁ¸À²Àº 6.0%¿´´Ù. º´±â¿¡ µû¸¥ 1³â »ýÁ¸À² ¹× Áß°£ »ýÁ¸±â°£Àº °¢°¢ º´±â IIIA¿¡¼­ 28.6%, 6.5°³¿ù, º´±â IIIB¿¡¼­ 50.3%, 13°³¿ùÀÌ¿´´Ù. ´Üº¯¼ö ºÐ¼®¿¡¼­ »ýÁ¸À²¿¡ ¿µÇâÀ» ¹ÌÄ¡´Â ¿¹ÈÄÀÎÀڷδ T º´±â, º´±â, ¹æ»ç¼± Ä¡·á Á÷ÈÄÀÇ ¹ÝÀÀÀÌ Åë°èÇÐÀûÀ¸·Î Àǹ̰¡ ÀÖ¾ú°í(P£¼0.05) ¿¬·É, ¼ºº°, º´¸®ÇÐÀû ¼Ò°ß, N º´±â, ¼â°ñ»ó ¸²ÇÁÀý ÀüÀÌ À¯¹«, È­ÇÐ ¿ä¹ý ½ÃÇàÀ¯¹« µîÀº Åë°èÇÐÀûÀ¸·Î Àǹ̰¡ ¾ø¾ú´Ù(P£¾0.1). ±×¿Ü Ä¡·áÀü Àü½Å»óÅ´ Åë°èÇÐÀû Àǹ̴ ¾ø¾úÁö¸¸ »ýÁ¸À²¿¡ ¿µÇâÀ» ÁÖ´Â °æÇâÀ» º¸¿©ÁÖ¾ú´Ù(0.05£¼P£¼0.1). ´Ùº¯¼ö ºÐ¼®»ó º´¸®ÇÐÀû ¼Ò°ß, ¹æ»ç¼±Ä¡·áÁ÷ÈÄÀÇ ¹ÝÀÀÀÌ ÀǹÌÀִ¿¹ÈÄÀÎÀÚ¿´°í T º´±â´Â Åë°èÇÐÀûÀ¸·Î Àǹ̴ ¾ø¾úÁö¸¸ »ýÁ¸À²°ú °ü·ÃµÈ °æÇâÀ» º¸¿©ÁÖ¾ú´Ù. ÃßÀû±â°£ Áß 20¿¹¿¡¼­ ¿ø°ÝÀüÀÌ°¡ °üÂûµÇ¾úÀ¸¸ç ±×Áß °ñÀüÀÌ°¡ 10¿¹, ³ú ÀüÀÌ 3¿¹, °£ ÀüÀÌ 3¿¹, ÆóÀüÀÌ 1¿¹¿´°í ±×¿Ü´Â ´Ù¹ßÀûÀ¸·Î ¹ß»ýÇÏ¿´´Ù.

°á ·Ð: ºñ¼Ò¼¼Æ÷Æó¾Ï ȯÀÚ¿¡¼­ ÀüÅëÀûÀÎ ¹æ»ç¼± ´Üµ¶ Ä¡·á ¶Ç´Â À¯µµÈ­Çпä¹ýÀ» º´ÇàÇÏ´Â °Í¸¸À¸·Î´Â Àå±â»ýÁ¸À²À» ±â´ëÇϱ⠾î·Á¿ì¸ç Á»´õ Àû±ØÀûÀÎ Ä¡·á¹æ¹ýÀÇ µµÀÔÀÌ ÇÊ¿äÇÑ´Ù. ÀúÀÚµéÀÇ º´¿ø¿¡¼­´Â ±¹¼Ò Á¦¾îÀ²À» ³ôÀ̱â À§ÇÏ¿© ¹æ»ç¼±Ä¡·á¿Í ÇÔ²² º´ÇàÈ­Çпä¹ýÀ» ½ÃÇàÇÑÈÄ °¡´ÉÇÑȯÀÚ¸¦ ´ë»óÀ¸·Î ÇÏ¿© ¼ö¼úÀÇ Àû¿ëÀ» ½ÃÇàÇÏ°í ÀÖ¾î ±× °á°ú°¡ ÁÖ¸ñµÈ´Ù.
Purpose: This study was done to evaluate the survival rate and prognostic factors of patients with inoperable non-small cell lung cancer(NSCLC) treated with radiation therapy.

Materials and Methods: A retrospective analysis was undertaken of 62 patients who had inoperable NSCLC treated with radiation therapy from January 1991 through December 1993. According to AJCC staging, stage ¥²A was 14 patients and stage ¥²B was 48 patients. Forty Gy to 70.2Gy to the primary tumor site was delivered with daily fractions of 1.8Gy or 2Gy, 5 days per week. Thirty-seven patients received neoadjuvant chemotherapy.

Results: Complete, partial and no response to radiation therapy were 3 patients, 34 patients and 25 patients, respectively. The median survival period of all patients was 11 month. One year survival rate, 2 year survival rate and 5 year survival rate for all patients were 45.0%, 14.3%, and 6.0% respectively. The median survival period was 6.5 months in stage ¥²A and 13 months in stage ¥²B. One year survival rates were 28.6% in stage ¥²A and 50.3% in stage ¥²B. In univariaite analysis, prognostic factors affecting survival were T-staging, AJCC staging, and response after radiation therapy (P£¼0.05). Pretreatment peformance status affected survival but was not statistically significant (0.05£¼P£¼0.1). Survival was not affected by age, sex, pathologic finding, N staging, supraclavicular lymph node status, and neoadjuvant chemotherapy (P£¾0.1). In multivariate analysis, pathology and response to radiation therapy are independently significant prognostic factor. T stage was marginally significant (P=0.0809). During follow-up duration, distant metastasis developed in 20 patients-bone metastasis in 10 patients, brain metastasis in 3 patients, liver mentastasis in 3 patients, contralateral lung metastasis in 1 patients and multiple metastases in 3 patients.

Conclusion: Conventional radiotherapy alone or combined chemoradiotherapy are unlikely to achieve long term survival in patients with NSCLC. Surgery after concurrent chemoradiotherapy is tried to improve the local control in our hospital

Å°¿öµå

Non-small cell cancer, Radiation therapy, Prognostic factor
¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸
µîÀçÀú³Î Á¤º¸
ÁÖÁ¦ÄÚµå
ÁÖÁ¦¸í(Target field)
¿¬±¸´ë»ó(Population)
¿¬±¸Âü¿©(Sample size)
´ë»ó¼ºº°(Gender)
Áúº´Æ¯¼º(Condition Category)
¿¬±¸È¯°æ(Setting)
¿¬±¸¼³°è(Study Design)
¿¬±¸±â°£(Period)
ÁßÀç¹æ¹ý(Intervention Type)
ÁßÀç¸íĪ(Intervention Name)
Å°¿öµå(Keyword)
À¯È¿¼º°á°ú(Recomendation)
One year survival rate, 2 year survival rate and 5 year survival rate for all patients were 45.0%, 14.3%, and 6.0% respectively.
¿¬±¸ºñÁö¿ø(Fund Source)
±Ù°Å¼öÁØÆò°¡(Evidence Hierarchy)
ÃâÆdz⵵(Year)
Âü¿©ÀúÀÚ¼ö(Authors)
´ëÇ¥ÀúÀÚ
DOI
KCDÄÚµå
ICD 03
°Ç°­º¸ÇèÄÚµå